CHC Guide - 2021 - 207

Readers
There's a life
behind every test
When care is as critical as having answers,
the portable     can
deliver reliable,   for respiratory
tract infections. Test single samples or
adapt your workflow by testing in batches.
Life moves fast-and now testing does too.
   
BD, the BD Logo and Veritor are trademarks of Becton, Dickinson and
Company or its affiliates. ©2021 BD. All rights reserved. March 2021
* Faster access to test results:
BD Veritor™
The new wireless BD Veritor™
Plus System
Plus System
provides health-care providers and laboratorians
in physician offices, clinics, hospitals, and
integrated delivery networks (IDNs) with
objective, lab-quality immunoassay test results
within minutes. This fast and accurate solution
streamlines the point-of-care (POC) diagnostic
workflow and allows providers to quickly review
patient results and determine the appropriate
treatment in a single consultation. The new
system can help detect infectious diseases
such as influenza A and B, respiratory syncytial
virus (RSV), and group A strep while the patient
is still on site, which can enable faster decisionmaking
for an earlier intervention opportunity.
Help inform appropriate and
targeted treatment decisions
* Improved workflow:
The BD Veritor™
Plus
Analyzer improves
workflow with an
Analyze Now or Walk
Away mode, providing test results
(with a print-enabled function) and aiding in
decision-making while the patient is on site
* Improved traceability: The BD Veritor™
InfoScan module can scan 3 different
identifiers (operator ID, specimen ID, and
test kit/lot) that can be locally recorded,
printed, or downloaded, and reduces
hands-on time through automated
documentation
BD Veritor™
System Flu A+B
Test Kit
The first CLIA-waived flu A+B test referenced
against PCR, a higher sensitivity standard
than culture. Device is ready to insert into
reader 10 minutes after sample is added.
* Positive percent agreement (A/B): 82.1%/74.6
* Negative percent agreement (A/B): 98.6%/99.6%
* Positive agreement vs. PCR for current visual
read rapid test ranges from 10% to 70%
* Streamlined workflow: Provides a digital result in
<11 minutes, with <50 seconds of hands-on time
#256045
(992-0002)........................................... 30/box
CPT®
21MS3390
BD Veritor™
System Group A
Strep Test
The first CLIA-waived digital
immunoassay (DIA) for the rapid detection of
Group A strep (GAS) with an instrumented
result. Test device is ready to insert into
reader 5 minutes after sample is added.
Once the test device is inserted in the
reader, an objective, digital test result is
displayed in 10 seconds.
* Sample type: Throat swab sample
* Sensitivity*: 95.4%
* Specificity*: 95.7%
#256040
Codes: Influenza A: 87804QW† / Influenza B: 87804-59†;
Using the Objective and Differentiated Reader System: 87999†
(992-0006)........................................... 30/box
CPT®
Code: 87880QW†
*Reference method: Bacterial culture; data from package insert.
To order, visit: www.henryschein.com/medical
BD Veritor™
System RSV
CLIA-Waived Kit
The first CLIA-waived RSV test referenced
against a higher sensitivity standard than
culture. Test device is ready to insert into
reader 10 minutes after sample is added.
The same sample processed for RSV can
also be used for flu A+B. Digital results
displayed in 10 seconds.
* Sample type: NP swab sample
* Positive percent agreement (PPA): 81.6%
* Negative percent agreement: (NPA): 99.1%
#256038
(121-7553)........................................... 30/box
CPT®
Code: 87807QW†
207
* Modularity: Provides a unique solution to
meet each testing site's preference
* Connectivity: BD Veritor™
InfoSync module
provides the same benefits as BD Veritor™
InfoScan. Connects and documents test
results across multiple sites and can
integrate with a hospital electronic medical
record or laboratory information system
* Advanced particle technology: Enhances
sensitivity by using a proprietary process
to produce highly stable, modified colloidal
metal particles.
* Adaptive read technology: Compensates
for background. Nonspecific binding helps
improve specificity to reduce false-positive
results
#256066
(126-5527)...................................................ea
POINT-OF-CARE TESTING

http://bdveritor.com http://www.henryschein.com/redirect.aspx?did=medical&returnurl=/us-en/Shopping/ProductDetails.aspx?productid=1265527&CatalogName=MEDICAL&utm_source=Medical&utm_medium=Nxtbook&utm_campaign=medical-annual-ref-guide-2021&utm_term=1265527 http://www.henryschein.com/redirect.aspx?did=medical&returnurl=/us-en/Shopping/ProductDetails.aspx?productid=9920002&CatalogName=MEDICAL&utm_source=Medical&utm_medium=Nxtbook&utm_campaign=medical-annual-ref-guide-2021&utm_term=9920002 http://www.henryschein.com/redirect.aspx?did=medical&returnurl=/us-en/Shopping/ProductDetails.aspx?productid=9920006&CatalogName=MEDICAL&utm_source=Medical&utm_medium=Nxtbook&utm_campaign=medical-annual-ref-guide-2021&utm_term=9920006 http://www.henryschein.com/redirect.aspx?did=medical&returnurl=/us-en/Shopping/ProductDetails.aspx?productid=1217553&CatalogName=MEDICAL&utm_source=Medical&utm_medium=Nxtbook&utm_campaign=medical-annual-ref-guide-2021&utm_term=1217553 http://www.henryschein.com/medical

CHC Guide - 2021

Table of Contents for the Digital Edition of CHC Guide - 2021